Shannah Murland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shannah Murland has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Amr Heikal
Department of Oncology, University of Alberta, Edmonton, AB T6G 1Z2, Canada
1 shared publication - Beena Kunheri
Kent Oncology Center, Maidstone and Tunbridge Wells NHS Trust, Maidstone, ME16 9QU, UK
1 shared publication - Ben Burke
Department of Oncology, University of Alberta, Edmonton, AB T6G 1Z2, Canada
1 shared publication Clarence Wong
Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, AB T6G 1Z2, Canada
1 shared publication- Eugene Yip
Department of Oncology, University of Alberta, Edmonton, AB T6G 1Z2, Canada
1 shared publication - Kurian Joseph
Department of Oncology, University of Alberta, Edmonton, AB T6G 2R3, Canada
1 shared publication
Latest Publications
- Open Access
- 31 August 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (9) , 519
Practical Considerations in the Radiotherapy Treatment Planning for SBRT Pancreas Program
Pancreatic ductal adenocarcinoma is one of the most aggressive tumours, with an estimated 5-year overall survival rate of 5% and median survival of 5–11 months. Approximately one third of patients die of complications due to local disease progression, especially among patients with borderline resectable or locally advanced disease; hence achieving local control is significant for improved survival outcomes. Stereotactic body radiotherapy (SBRT) allows safe and effective delivery of ablative doses of radiation and is associated with improved locoregional tumour control and progression free survival. Our article describes the rationale and the safe and effective delivery of Linac-based SBRT treatment for pancreatic cancer.
- 31 August 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (9) , 519
Open AccessPractical Considerations in the Radiotherapy Treatment Planning for SBRT Pancreas Program
Pancreatic ductal adenocarcinoma is one of the most aggressive tumours, with an estimated 5-year overall survival rate of 5% and median survival of 5–11 months. Approximately one third of patients die of complications due to local disease progression, especially among patients with borderline resectable or locally advanced disease; hence achieving local control is significant for improved survival outcomes. Stereotactic body radiotherapy (SBRT) allows safe and effective delivery of ablative doses of radiation and is associated with improved locoregional tumour control and progression free survival. Our article describes the rationale and the safe and effective delivery of Linac-based SBRT treatment for pancreatic cancer.